Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;53(1):8-21.
doi: 10.1111/apt.16072. Epub 2020 Sep 16.

Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia

Alexander C Ford  1   2 , Paul Moayyedi  3 , Christopher J Black  1   2 , Yuhong Yuan  3 , Sajesh K Veettil  4 , Sanjiv Mahadeva  5 , Kirati Kengkla  6 , Nathorn Chaiyakunapruk  4 , Yeong Yeh Lee  7   8   9
Affiliations

Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia

Alexander C Ford et al. Aliment Pharmacol Ther. 2021 Jan.

Abstract

Background: Functional dyspepsia (FD) is a relapsing and remitting condition affecting between 5% and 10% of people. Efficacious therapies are available, but their relative efficacy is unknown.

Aim: To perform a systematic review with network meta-analysis to resolve this uncertainty.

Methods: We searched the medical literature through July 2020 for randomised controlled trials (RCTs) assessing efficacy of drugs for adults with FD, compared with each other, or placebo. Trials reported a dichotomous assessment of symptom status after completion of therapy. We pooled data using a random effects model. Efficacy was reported as a pooled relative risk (RR) of remaining symptomatic with a 95% confidence interval (CI) to summarise efficacy of each comparison tested. Relative ranking was assessed with surface under the cumulative ranking curve (SUCRA) probabilities.

Results: We identified 71 eligible RCTs (19 243 participants). Tricyclic antidepressants (TCAs) were ranked second for efficacy (RR of remaining symptomatic = 0.71; 95% CI 0.58-0.87, SUCRA 0.87), and first when only low risk of bias trials were included. Most RCTs that used TCAs recruited patients who were refractory to other drugs included in the network. Although sulpiride or levosulpiride were ranked first for efficacy (RR = 0.49; 95% CI 0.36-0.69, SUCRA 0.99), trial quality was low and only 86 patients received active therapy. TCAs were more likely to cause adverse events than placebo.

Conclusions: TCAs, histamine-2 receptor antagonists, standard- and low-dose proton pump inhibitors, sulpiride or levosulpiride, itopride and acotiamide were all more efficacious than placebo for FD.

PubMed Disclaimer

References

REFERENCES

    1. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150:1257-1261.
    1. Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380-1392.
    1. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.04.014
    1. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut. 2007;56:321-327.
    1. Aro P, Talley NJ, Johansson SE, Agreus L, Ronkainen J. Anxiety Is linked to new-onset dyspepsia in the Swedish population: a 10-year follow-up study. Gastroenterology. 2015;148:928-937.

Publication types

Substances